'); } -->
Trimeris' largest investor is redoubling its efforts to force the Morrisville drug company to put itself up for sale.
Although Trimeris announced in December it would halt its research and development activity and evaluate other options for boosting its stock price, New York investment firm HealthCor wants the company to move faster to sell itself.
In a letter to Trimeris executives filed today with the Securities and Exchange Commission, HealthCor officials say they want to take two seats on the company's board of directors.
"We are not in favor of strategic transactions other than those involving a sale of the business," HealthCor officials wrote in the letter dated Feb. 1.
The firm owns nearly 18 percent of Trimeris' shares.
Trimeris was one of the Triangle's most promising drug-development companies, with a new AIDS drug called Fuzeon that analysts expected would be a huge seller. But its steep price tag and slow acceptance among patients and physicians has led to disappointing sales.
Trimeris shares rose 19 cents to $6.61 in midday trading. The stock is down 52 percent in the past year.
Get it all with convenient home delivery of The News & Observer.
The News & Observer is pleased to be able to offer its users the opportunity to make comments and hold conversations online. However, the interactive nature of the internet makes it impracticable for our staff to monitor each and every posting.
Since The News & Observer does not control user submitted statements, we cannot promise that readers will not occasionally find offensive or inaccurate comments posted on our website. In addition, we remind anyone interested in making an online comment that responsibility for statements posted lies with the person submitting the comment, not The News and Observer.
If you find a comment offensive, clicking on the exclamation icon will flag the comment for review by the administrators, we are counting on the good judgment of all our readers to help us.